Articles tagged with Gastrointestinal Neoplasms
A new study uses patient-specific tumor organoids to identify the most effective chemotherapy protocol for treating advanced stages of colon and appendiceal cancer. The approach shows promise in tailoring treatment to individual patients, potentially increasing life expectancy.
Researchers biofabricated human colorectal cancer organoids to understand how tumors grow in their natural microenvironment and respond to treatments. The study replicated native tumor tissue in a laboratory model and validated its effects on whole-body physiology, paving the way for new therapies targeting the extracellular matrix.
Research found that miR-133b levels were significantly lower in FAP-associated Desmoid tumors than in sporadic Desmoid tumors. SIRT1 mRNA levels were up-regulated in FAP-associated Desmoid tumor, suggesting a novel mechanism underlying progression.
Researchers used infrared microscopes and artificial intelligence to classify tissue samples of colorectal cancer, achieving a sensitivity of 100% and specificity of 93%. The method allows for rapid diagnosis and can predict the course of the disease, enabling doctors to choose the appropriate therapy.
A comprehensive survey reveals that bacteria are widespread in human tumors, differing by tumor type. Different tumor types harbor distinct microbiomes, with breast tumors displaying a rich and diverse community of bacteria.
A comprehensive epigenetic study on human tumor organoids reveals their potential as a reliable model for cancer research. The findings validate the use of these samples in biomedical research and pharmaceutical development, opening up new avenues for discovering anti-cancer treatments.
Researchers discovered that cancer stem cells' ability to synthesise proteins is the essence of their pluripotency and contributes to unlimited tumour growth. By blocking this capacity, tumours can be halted in an irreversible manner.
Scientists used 3D models to study cancer cell DNA behavior, validating the use of these models for cancer research. The research team characterized the epigenetic fingerprint of human cancer organoids, showing that they closely resemble patient tumors and can be used to develop new oncology treatments.
A study found that loss of p16 expression is associated with shortened overall survival in esophageal cancer patients, while high Ki67 labeling index is an independent prognosticator of poor survival. Rare homozygous 9p21 deletions can lead to complete loss of p16 expression.
A phase II clinical trial found that immunotherapy significantly shrinks or clears tumors in patients with non-metastasized colon cancer. In the MSI subtype, all 20 patients (100%) benefited from the therapy, while 25% of those with MSS tumors also responded well.
Researchers found that Bifidobacteria accumulate in tumors and activate the stimulation of interferon genes pathway, enhancing anti-tumor efficacy of CD47 immunotherapy. Supplementation with Bifidobacteria improved treatment response in mice with previously non-responsive tumors.
Researchers found that gut bacteria can accumulate within tumors and enhance the effectiveness of anti-CD47 immunotherapy. The study suggests that a probiotic might improve treatment outcomes, and identifying specific bacterial strains is crucial for future research.
Researchers at Mayo Clinic have found that combining density of immune cells with analysis of tumor budding can improve accuracy in predicting patient survival for patients with stage III colon cancer. This method provides important data on patient survival and may lead to personalized treatment recommendations.
Researchers developed a novel anti-CEACAM antibody for fluorescence visualization of colorectal tumors and metastases. The antibody targets multiple CEACAMs, which can lead to improved detection of tumor margins and metastases with variable expression of CEA.
A University of Colorado Cancer Center study found that patients with locally advanced rectal cancer who received lower-than-recommended doses of neoadjuvant chemotherapy experienced a complete response and tumor shrinkage similar to those receiving the full dose.
Researchers found that certain bacteria, including F. nuc and Moraxella osloensis, are more prevalent in younger patients' tumors than older patients', suggesting a potential link between gut bacteria and the rising incidence of colorectal cancer in people under 45.
Researchers developed an integrated genomic approach to predict which lung cancer patients will respond to immunotherapy. They found a correlation between tumor mutational burden and tumor purity, and corrected TMB estimates improved prediction of overall survival.
A new study from Northwestern Medicine reports the first guidelines for treating sebaceous carcinoma, a cancer of oil glands that can be found on the skin or in the eye. The guidelines provide clear direction for treating these tumors, which may result in fewer deaths.
Enteric glial cells convert into tumor growth promoters when exposed to secretions from colon tumors, regulating important intestinal functions and interacting with cancer stem cells. The study identifies key molecules involved in this process and offers new potential targets for cancer therapies.
Researchers discover DEPDC5, a chromosome 22q-targeting tumor suppressor, silenced by mutations in GISTs. The gene's inactivation promotes GIST cell proliferation and reduces sensitivity to KIT inhibitors.
New research reveals creatine powers CD8 T cells' fight against cancer by storing and distributing energy. Creatine supplementation enhances existing immunotherapies, including PD-1/PD-L1 blockade therapy, leading to significant tumor eradication rates.
A novel molecular marker has been identified for tumor aggression in neurofibromatosis type 1 (NF1), a rare genetic syndrome. ALT-positive tumors were found to be more aggressive, occurring mostly in gliomas.
A new approach to identifying killer T lymphocytes in patients with gastrointestinal tumors has been developed, which can hone in on unique mutations expressed in cancer cells. This breakthrough could lead to the development of personalized and effective cell therapies for patients who do not respond to current immunotherapies.
A liquid biopsy test can predict which patients with colorectal cancer are likely to relapse after surgery, and guide treatment. The test identified patients who were more or less likely to remain disease-free two years after chemotherapy.
A simple and sensitive urine test has been developed to detect colon cancer in mice, changing the color of urine to signal growing tumors. The test uses nanosensors that break down when cut by enzymes released by tumors, producing a blue color change that can be seen with the naked eye.
Researchers developed a nonwoven fabric bioabsorbable spacer that creates a space between healthy and cancerous tissues during particle therapy, preserving distance between tumors and normal organs. The spacer safely absorbs by the body without causing serious complications.
Researchers at Champalimaud Centre for the Unknown discovered a cell-competition mechanism called fitness fingerprints that allows cancer cells to disguise themselves as healthy cells. By blocking this mechanism, they found that tumour growth can be slowed down, but not eliminated.
Researchers from CNIO have found that high levels of URI protein protect mice from radiation-induced intestinal damage, while low or no detectable levels lead to gastrointestinal syndrome and death. The study opens up new avenues for treating and preventing gastrointestinal syndrome by inhibiting c-MYC.
Researchers at Massachusetts General Hospital have discovered a method to repurpose immunosuppressive regulatory T cells into inflammatory cells that intensify an antitumor immune response. This approach primes tumors for immune checkpoint blockade, increasing the effectiveness of cancer therapies.
Researchers analyzed colon cancer proteins and genes, uncovering novel biological mechanisms and potential new therapeutic strategies. The study provides a systematic catalog of proteins produced by colon cancer tumors and adjacent normal tissues, including insights into unexpected gene behavior.
Researchers at Columbia University School of Engineering and Applied Science have developed a system called BSCC, which enables rapid screening of engineered bacterial therapies in vitro. They successfully tested a potent therapy for colon cancer using a novel bacterial toxin combined with an optimal drug delivery genetic circuit.
Researchers at Boston Children's Hospital and MIT have developed nanobodies that can target the tumor micro-environment, allowing for more effective treatment of solid tumors. The nanobodies were tested in mouse models of melanoma and colon cancer, showing promising results in slowing tumor growth and improving survival rates.
A combination of ipilimumab and nivolumab demonstrated clinical benefit among patients with high-grade neuroendocrine carcinoma in a phase II clinical trial. The therapy showed an overall response rate of 24% and improved progression-free survival, offering new hope for this patient population.
A study by Weill Cornell Medicine found that consuming high-fructose corn syrup causes mice with colon cancer to develop larger tumors. The researchers discovered a molecular mechanism by which the sweetener fuels tumor growth and suggest blocking this effect could lead to new cancer treatments.
Researchers found that early-life microbiota play a crucial role in regulating immune responses and preventing colon cancer in adulthood. The absence of microbiota in early life can lead to enhanced pro-inflammatory gene expression and an accumulation of immune cells that suppress tumor growth.
Researchers discover that eosinophils, previously associated with allergies and asthma, can kill colon cancer cells. The study found a clear correlation between the number of eosinophils in tumors and disease severity, suggesting these white blood cells may play a role in cancer treatment.
A new approach to treating tumors has been discovered by regulating vascularization through a gene that is overexpressed in the tumor vasculature. By targeting the insulin receptor, scientists hope to deliver treatments more accurately and effectively.
Researchers created a patient-specific tumor 'organoid' model to identify the most effective treatment for each tumor. The study successfully generated organoids for nine out of 12 patients, demonstrating the potential for personalized medicine.
A Finnish study found that men who participated in the national colorectal cancer screening programme were less likely to require emergency surgery, chemotherapy, and incomplete tumour removals. The benefits of screening were particularly pronounced among male patients with left-sided colorectal cancer.
Researchers report a 100% major pathological response rate in early-stage colon cancers with mismatch repair deficiencies treated with nivolumab and ipilimumab. The regimen was well-tolerated, and patients underwent radical resection without delays.
A new imaging method targets cancer-associated fibroblasts to diagnose widespread tumors like breast, colon, and pancreas cancer with better accuracy and less inconvenience. The tracer shows high tumor uptake and image contrast, making it a promising strategy for detection and treatment of malignant tumors.
Researchers found a combination treatment combining a CK2 inhibitor with an immune checkpoint inhibitor dramatically increased antitumor activity, eliminating over 60% of tumors in mouse models. The study suggests manipulating the tumor microenvironment may improve clinical outcomes for cancer patients.
A new study reveals that c-MYC induces the production of a transcription factor, increasing the numbers of stem cells in the intestinal epithelium and contributing to adenoma formation. The loss of Ap4 protein leads to reduced tumors and longer survival, indicating its role in controlling intestinal homeostasis.
Researchers developed a predictive model using liquid biopsies and serial blood samples from patients with advanced colorectal cancer treated with anti-EGFR therapies. The model accurately predicted personalized waiting times for disease progression, outperforming traditional tumor genotyping methods.
A study published in Nature Communications reveals that inhibiting Jagged 1 protein can prevent colon and rectal tumour growth, even removing existing tumours. This approach may offer a promising therapeutic strategy for selectively targeting malignant stem cells in colon cancer.
Researchers at Boston University School of Medicine have identified c-Cbl as a potential target protein in colon cancer. High levels of c-Cbl were found to be associated with longer patient survival rates.
Lutathera therapy has been shown to provide significantly longer time to deterioration of quality of life compared to hormone therapy alone, with median times of 28.8 months vs 6.1 months for global health status and 25.2 months vs 11.5 months for physical functioning.
Researchers have developed a new nuclear medicine procedure that can safely and effectively detect cancerous gastrointestinal and pancreatic neuroendocrine tumors. The novel radiolabeled tracer Ga-OPS202 has been shown to improve imaging contrast and sensitivity for detecting primary tumors or liver metastases.
Researchers found that SHP2 inhibitors are effective against lung and pancreatic cancers, which share the same genetic error. The new class of drugs may help treat drug-resistant tumors by reverting cancer cells to being susceptible to other drugs.
Researchers at Stockholm University discovered a new mechanism regulating stem cells in the fruit fly's intestine and found that a specific protein can slow tumour growth. The study sheds light on how intestinal diseases occur and may contribute to the development of new medicine to prevent and cure them.
A study published in the Genes & Development journal reveals that tumor cells can survive even without Ras genes if Erf is also lost, casting doubt on the effectiveness of potential treatments. The researchers found that eliminating ERF allows mouse stem cells to grow and differentiate in the absence of RAS genes.
Researchers analyzed 5,298 patients with surgically removed ampullary tumors and found no survival benefit from adjuvant therapy. Patients receiving additional chemotherapy or radiation therapy did not show improved stage-specific survival rates compared to those who underwent surgery alone.
Researchers at IRB Barcelona have discovered that immune system-stimulating treatments combined with a TGF-beta inhibitor are effective against colon cancer. They developed a mouse model that mimics advanced human colon cancer, allowing them to examine how cancer cells evade the immune system.
A team of researchers developed a fluorescent sensor, TiY, that selectively stains tumor initiating cells (TICs) in various cancer tissues. The sensor can distinguish TICs from non-TICs and inhibit sphere formation, leading to suppressed tumor growth in mice xenograft models.
Researchers at Stanford University School of Medicine developed a cancer vaccine that eliminates tumors in mice by stimulating immune cells within the tumor site. The treatment showed promise for many types of cancers and could potentially replace or complement existing immunotherapy approaches.
A new UCLA study found that a high-cholesterol diet can accelerate the formation of tumors in the colon by speeding up intestinal stem cell division. The research identified a molecular pathway that could serve as a new target for colon cancer treatment.
A novel hypothesis proposes that animal diversification resulted from a revolution within the animals' own biology, rather than in surrounding chemistry. Cells with stem cell properties are vital for multicellular life, and tumor cells have developed mechanisms to maintain these properties despite high oxygen levels.
A study by University of Chicago researchers found that specific strains of commensal bacteria can improve response rates to immunotherapy for patients with advanced melanoma. The presence of these beneficial bacteria enhances T-cell infiltration and killing of cancer cells, leading to a vigorous and durable response.
A study found that microRNA-31 accelerates intestinal stem cell growth, potentially leading to bowel cancer. The molecule's levels increased after radiation exposure, suggesting a role in regeneration, while also promoting tumor growth.
A new study found that administering a histamine-producing probiotic reduced inflammation and suppressed colon tumors in mice. The probiotic increased expression of the enzyme histidine decarboxylase, which converts histidine to histamine, resulting in decreased glucose uptake and tumor formation.